Eli Lilly and NVIDIA invest in AI-driven pharmaceutical innovation
The new AI partnership between NVIDIA and Lilly aims to improve drug discovery by linking large-scale data, accelerated computing and laboratory research over the next five years.
NVIDIA and Eli Lilly have announced a joint AI co-innovation lab aimed at advancing drug discovery by combining AI with pharmaceutical research.
The partnership combines Lilly’s experience in medical development with NVIDIA’s expertise in accelerated computing and AI infrastructure.
The two companies plan to invest up to $1 billion over five years in research capacity, computing resources and specialist talent.
Based in the San Francisco Bay Area, the lab will support large-scale data generation and model development using NVIDIA platforms, instead of relying solely on traditional laboratory workflows.
Beyond early research, the collaboration is expected to explore applications of AI across manufacturing, clinical development and supply chain operations.
Both NVIDIA and Eli Lilly claim the initiative is designed to enhance efficiency and scalability in medical production while fostering long-term innovation in the life sciences sector.
Would you like to learn more about AI, tech and digital diplomacy? If so, ask our Diplo chatbot!